Durham Katelin, Atagozli Tyler, Elliott David E, Ince M Nedim
Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA.
Iowa City Veterans Affairs Medical Center, 601 Highway 6 W, Iowa City, IA 52246, USA.
Biomedicines. 2025 Feb 17;13(2):491. doi: 10.3390/biomedicines13020491.
Inflammatory bowel diseases (IBDs) comprise a group of chronic gastrointestinal disorders characterized by periods of relapse and remission. The mainstay of treatment is medical, involving medications such as steroids, immune modulators, monoclonal antibodies (categorized as biologics), and small molecules. These medications can provide profound therapeutic benefits, but they can also cause severe and irreversible toxicities. Clinicians may utilize laboratory tests in the diagnosis and management of IBD including assessment of disease activity, monitoring medication response or toxicity, surveillance of infectious complications, and detection of nutritional deficiencies. Routine use of laboratory tests may help clinicians avoid reactivation of life-threatening infections such as tuberculosis or hepatitis B virus upon initiation of immune suppressive therapy. They can also be used to detect vitamin deficiencies such as B12 deficiency, which has the potential to cause irreversible neurologic damage. While some laboratory tests constitute established practices, the utility of newer tests such therapeutic drug monitoring (TDM) in the era of biologics is an evolving topic. Although clinical assessment with imaging, endoscopic, and histopathological examination is standard practice, laboratory tests serve as valuable adjuncts. We aim to explore the broad range of laboratory tests available to clinicians and to summarize their application in the current management of IBD in daily clinical practice, with special attention to updates in therapeutic drug monitoring.
炎症性肠病(IBD)是一组慢性胃肠道疾病,其特征为病情有复发和缓解期。治疗的主要手段是药物治疗,涉及使用类固醇、免疫调节剂、单克隆抗体(归类为生物制剂)和小分子药物等。这些药物能带来显著的治疗益处,但也可能导致严重且不可逆的毒性。临床医生在IBD的诊断和管理中可能会利用实验室检查,包括评估疾病活动度、监测药物反应或毒性、监测感染并发症以及检测营养缺乏情况。常规进行实验室检查可能有助于临床医生避免在开始免疫抑制治疗时重新激活如结核病或乙型肝炎病毒等危及生命的感染。它们还可用于检测维生素缺乏,如维生素B12缺乏,其有可能导致不可逆的神经损伤。虽然一些实验室检查已成为既定做法,但在生物制剂时代,诸如治疗药物监测(TDM)等新检查的效用仍是一个不断发展的话题。尽管通过影像学、内镜和组织病理学检查进行临床评估是标准做法,但实验室检查是有价值的辅助手段。我们旨在探讨临床医生可用的广泛实验室检查,并总结它们在日常临床实践中IBD当前管理中的应用,特别关注治疗药物监测的更新情况。